Dowling, David J. http://orcid.org/0000-0003-1095-6156
Barman, Soumik http://orcid.org/0000-0002-3641-2125
Smith, Alyson J.
Borriello, Francesco
Chaney, Danielle
Brightman, Spencer E.
Melhem, Gandolina
Brook, Byron
Menon, Manisha
Soni, Dheeraj
Schüller, Simone
Siram, Karthik http://orcid.org/0000-0002-7669-3945
Nanishi, Etsuro
Bazin, Hélène G.
Burkhart, David J.
Levy, Ofer http://orcid.org/0000-0002-5859-1945
Evans, Jay T. http://orcid.org/0000-0001-6602-0272
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (75N93019C00044, 5R21AI137932-02, 75N93019C00044, 272201800047C, HHSN272200900036C, HHSN272201800047C)
Article History
Received: 6 June 2022
Accepted: 12 September 2022
First Online: 18 October 2022
Competing interests
: D.J.D., F.B., B.B., D.S., E.N., H.G.B., D.B., O.L. and J.T.E. are named inventors on several patent applications related to vaccine adjuvants. J.T.E., D.B. and H.G.B. are employees and co-founders of Inimmune Corporation. F.B. has signed consulting agreements with Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Sana Biotechnology, Inc., and F. Hoffmann-La Roche Ltd. These commercial relationships are unrelated to the current study. Rest of the authors do not have any competing interests.